Cynthia Flagg sits with her husband Charles, who took part in an early stage trial of Biogen's drug Aducanumab following his diagnosis with Alzheimer's disease, at their home in Jamestown, Rhode Island, US. Reuters
Leroy Hood, Tribune News Service
My personal journey with Alzheimer’s began in 2005 when my wife, Valerie, received her diagnosis with this terrible disease, one that robs the afflicted of their minds and forces family and friends to watch with dread as their loved one slowly disappears.
Stunned by the news, I was overwhelmed with grief for my life partner and the loss of our future together. Valerie was a vivacious, energetic person with a passion for education, which we shared. After her diagnosis, I began a quest to better understand the cause of the disease and to find new approaches and therapies that might prevent, delay or reverse its spread in others.
There is so much we don’t yet understand about Alzheimer’s disease, but its devastating impact is growing. In the US, there are 6.2 million patients, a number expected to more than double by 2050. In 2018, more than 120,000 Americans died from the disease, making it the nation’s sixth leading cause of death. Almost two-thirds of patients are women, but there is no explanation for this gender discrepancy. In the US, the cost of treatment and care for these patients for 2020 is estimated at more than $300 billion. The total cost, factoring losses in income, life savings and productivity, is many times higher.
Scientists have conducted more than 400 clinical drug trials over the last 14 years searching for a pharmaceutical cure. All have failed. This month, the Food and Drug Administration approved a Biogen drug, aducanumab, as a treatment to slow cognitive decline in Alzheimer’s patients. The FDA’s advisory committee, however, overwhelmingly recommended against approval because there is so little evidence in clinical trials that the drug works. Three members of the committee have resigned from the committee in protest of the agency’s decision.
The lack of progress in developing an effective drug, or a combination of drugs, that will treat the disease once it arises suggests that we’ve been looking at this problem in the wrong way. Instead, effective therapies may require systemic approaches based on the principles of science-driven wellness. In my own search for answers, I learned that some important discoveries are being made.
For instance, Michael Phelps, a UCLA biophysicist and the inventor of the PET scan (the technology that produces images of disease changes in the body), has found that some of the chemical changes in the brain as a person moves from wellness to Alzheimer’s disease occur from four to 10 years before any clinical diagnosis could be made. It should be possible to develop a blood test through clinical trials that can detect blood biomarkers reflecting those brain changes at a very early stage in the transition to illness. With such information, patients could begin treatment long before the disease has reached its traditional diagnosable stage.
But what kind of treatment would this be?
Just as we’ve long known that exercise, healthy diets and the avoidance of harmful habits such as smoking can stave off heart disease, studies have shown that a person’s lifestyle can play a big role on whether and how fast the disease progresses.
One researcher, Dale Bredesen, for example, has focused on a systems approach to stabilising the synaptic connections between nerve cells that are lost in this disease. He has begun studies to validate the idea that treatment should be “multimodal” — and based on correcting a patient’s unique deficiencies, assessed by analyzing their blood and other factors such as environmental toxins, diet, exercise and sleep.
In a groundbreaking study, a team of Finnish and Swedish researchers found that non-drug-based approaches can work as interventions for older adults with elevated risk for dementia.
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, also known as FINGER, was a two-year, double-blind, randomized controlled trial that included 1,260 people. The participants were placed into a program that included dietary guidance, exercise, cognitive training and social activities, along with intensive monitoring and management of metabolic and vascular health.
In essence, the participants who were selected to receive the interventions underwent something akin to a science-based wellness approach. There was some skepticism when the FINGER study was announced. Many of the interventions had been tried before on dementia patients, often with disappointing results. But the researchers weren’t convinced that these approaches were all dead ends. Exercise alone might not move the needle much. Cognitive training by itself might be relatively fruitless. Socialisation, in and of itself, might not do much. But the whole might be greater than the sum of its parts — and indeed it was.
By the end of the trial, the patients who had received the multiple interventions were far more likely than the control group to have maintained — and even improved — their cognitive functioning. Their memories were stronger. Their ability to pay attention and maintain that attention was better. The relationship between their thoughts and physical movements was sharper.
To maintain brain health, we need to intervene with multimodal therapies as early as possible. The key will be determining the particular susceptibilities of each individual and designing a combination of interventions specific to that person.
After three years of collaboration, a team of academician-scientists from the UAE, US and Sweden has designed and developed peptides believe to inhibit the progress of another group of proteins and protect the brain from the neurodegenerative Alzheimer’s Disease.
There is a new form of Alzheimer’s Disease (AD) identified as “Progressive Dysexecutive Syndrome (dAD), the onset of which is by age 40.
The cost of caring for America’s nearly 6 million Alzheimer’s disease patients is already $600 billion a year, factoring in the cost of uncompensated caregiving. Now, the Food and Drug Administration has approved a drug treatment that may or may not work
When the US Food and Drug Administration approved Biogen Inc.’s controversial Alzheimer’s drug Aduhelm earlier this month without firm evidence that the drug helps patients, it created concern that other unproven treatments might follow. That scenario is already here.
Top six cities of India have absorbed about 10.3 million squares feet of office space in third quarter of 2021, the highest volume recorded since first quarter of 2020.
United States President Joe Biden in a CNN town hall meeting said that the United States would go to war to defend Taiwan if China were to launch an invasion. The president’s statement created a flutter.
Mark Zuckerberg wants to rechristen Facebook Inc., giving the financial powerhouse — and social media hothouse — a fresh identity. While Zuckerberg’s corporate baby has handily weathered prior crises, boasts an enviable global footprint and continues to rake in massive profits, critics have turned it into a pinata for myriad good reasons. Zuckerberg seems to think the best response to all of this is cosmetic.
President Joe Biden and Congress’ top two Democrats strategised on Friday on how to give fresh impetus to their giant domestic legislation as the party continued scaling back the measure in an effort to break the deadlocks that have stalled it for months.